FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2462168748> ?p ?o ?g. }

• W2462168748 abstract "Abstract Abstract 4629 Background: Patients with refractory CLL have poor outcome despite currently used salvage treatment. Regimens based on high-dose corticosteroids seem to offer a promising treatment option in this scenario. High-dose methylprenisolone combined with rituximab (R-HDMP) demonstrated significant activity in relapsed/refractory CLL but serious infectious complications occurred in a substantial proportion of patients. Pilot data have shown that combination of dexamethasone and rituximab (R-Dex) may provide comparable results with less toxicity. Aims and Methods: We performed a retrospective analysis of the efficacy and safety of R-Dex in patients (pts) with CLL treated at two tertiary centers between April 2006 and February 2010. Patients received two versions of R-Dex regimen: the dose of rituximab was either 500 mg/m2 on day 1, 8, 15, 22 (375 mg/m2 in 1st cycle), repeated every 4 weeks (n=25) or 500 mg/m2 on day 1 (375 mg/m2 in 1st cycle) repeated every 3 weeks (n=16). The dose of dexamethasone was identical in both regimens: 320 mg per cycle (40 mg on day 1–4 and 10–13 or 15–18). Results: R-Dex was administered to 41 patients (19 males) with median age of 68 years (range, 44–81) indicated for treatment according to NCI-WG criteria. Autoimmune hemolytic anemia or thrombocytopenia was the only indication for the treatment in 7 patients. Rai stage III/IV was present in 37/41 pts. IgVH genes were unmutated in 24/29 pts with available results. Cytogenetic aberrations detected by FISH (n=33) revealed del 17p in 7 patients; del 11q in 11 patients; del 13q in 15 patients and trisomy 12 in 5 patients. Median number of previous therapies was 2 (0-8); 29/41 pts were previously treated with fludarabine-based regimens. The effect of R-Dex in evaluable patients without hemolysis (n=32) was: overall response rate (ORR), n= 21 (62%), complete remission (CR), n=6 (18%), partial remission (PR), n=15 (44%), stable disease (SD), n=4 (12%) and progressive disease (PD), n=5 (15%). All patients treated with R-Dex for autoimmune cytopenia achieved complete resolution of hemolysis. Grade III or IV toxicity included infections in 13 patients (32%), steroid diabetes in 6 patients (15%) and rituximab infusion-related side effects in 3 patients (7%). At the time of analysis (February 2010), median progression free survival (PFS) was 9 months; median overall survival has not been reached. There was no difference in ORR, PFS or OS between the two versions of R-Dex regimen. Conclusions: This pilot study shows that R-Dex is a feasible and effective treatment for relapsed/refractory CLL. In particular, R-Dex appears to be highly effective in CLL with autoimmune cytopenias. However, infectious toxicity remains a serious issue. In addition, long-term disease control can be expected in minority of patients only. Interestingly, higher dose of rituximab per cycle did not result in improved efficacy. Supported by research project MZO 00179906 from Ministry of Health, Czech Republic, by research grant MSM 0021620808 and by the Czech Leukemia Study Group for Life. Disclosures: Smolej: Roche: Honoraria; Bayer-Schering: Honoraria; Genzyme: Honoraria." @default.
• W2462168748 created "2016-07-22" @default.
• W2462168748 creator A5042672780 @default.
• W2462168748 creator A5049999011 @default.
• W2462168748 creator A5054654885 @default.
• W2462168748 creator A5063453097 @default.
• W2462168748 creator A5064830159 @default.
• W2462168748 creator A5065520471 @default.
• W2462168748 creator A5077793241 @default.
• W2462168748 creator A5090624182 @default.
• W2462168748 date "2010-11-19" @default.
• W2462168748 modified "2023-10-01" @default.
• W2462168748 title "Rituximab In Combination with High-Dose Dexamethasone: An Effective Treatment Option for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia" @default.
• W2462168748 doi "https://doi.org/10.1182/blood.v116.21.4629.4629" @default.
• W2462168748 hasPublicationYear "2010" @default.
• W2462168748 type Work @default.
• W2462168748 sameAs 2462168748 @default.
• W2462168748 citedByCount "0" @default.
• W2462168748 crossrefType "journal-article" @default.
• W2462168748 hasAuthorship W2462168748A5042672780 @default.
• W2462168748 hasAuthorship W2462168748A5049999011 @default.
• W2462168748 hasAuthorship W2462168748A5054654885 @default.
• W2462168748 hasAuthorship W2462168748A5063453097 @default.
• W2462168748 hasAuthorship W2462168748A5064830159 @default.
• W2462168748 hasAuthorship W2462168748A5065520471 @default.
• W2462168748 hasAuthorship W2462168748A5077793241 @default.
• W2462168748 hasAuthorship W2462168748A5090624182 @default.
• W2462168748 hasConcept C121332964 @default.
• W2462168748 hasConcept C126322002 @default.
• W2462168748 hasConcept C141071460 @default.
• W2462168748 hasConcept C142424586 @default.
• W2462168748 hasConcept C2777063308 @default.
• W2462168748 hasConcept C2777938653 @default.
• W2462168748 hasConcept C2778461978 @default.
• W2462168748 hasConcept C2779338263 @default.
• W2462168748 hasConcept C2780401358 @default.
• W2462168748 hasConcept C2780653079 @default.
• W2462168748 hasConcept C2781413609 @default.
• W2462168748 hasConcept C29730261 @default.
• W2462168748 hasConcept C71924100 @default.
• W2462168748 hasConcept C87355193 @default.
• W2462168748 hasConcept C90924648 @default.
• W2462168748 hasConceptScore W2462168748C121332964 @default.
• W2462168748 hasConceptScore W2462168748C126322002 @default.
• W2462168748 hasConceptScore W2462168748C141071460 @default.
• W2462168748 hasConceptScore W2462168748C142424586 @default.
• W2462168748 hasConceptScore W2462168748C2777063308 @default.
• W2462168748 hasConceptScore W2462168748C2777938653 @default.
• W2462168748 hasConceptScore W2462168748C2778461978 @default.
• W2462168748 hasConceptScore W2462168748C2779338263 @default.
• W2462168748 hasConceptScore W2462168748C2780401358 @default.
• W2462168748 hasConceptScore W2462168748C2780653079 @default.
• W2462168748 hasConceptScore W2462168748C2781413609 @default.
• W2462168748 hasConceptScore W2462168748C29730261 @default.
• W2462168748 hasConceptScore W2462168748C71924100 @default.
• W2462168748 hasConceptScore W2462168748C87355193 @default.
• W2462168748 hasConceptScore W2462168748C90924648 @default.
• W2462168748 hasLocation W24621687481 @default.
• W2462168748 hasOpenAccess W2462168748 @default.
• W2462168748 hasPrimaryLocation W24621687481 @default.
• W2462168748 hasRelatedWork W126125533 @default.
• W2462168748 hasRelatedWork W1923714325 @default.
• W2462168748 hasRelatedWork W1990815726 @default.
• W2462168748 hasRelatedWork W2022925103 @default.
• W2462168748 hasRelatedWork W2085074066 @default.
• W2462168748 hasRelatedWork W2260296716 @default.
• W2462168748 hasRelatedWork W2263371368 @default.
• W2462168748 hasRelatedWork W2326926256 @default.
• W2462168748 hasRelatedWork W2336988007 @default.
• W2462168748 hasRelatedWork W2462429923 @default.
• W2462168748 hasRelatedWork W2485364093 @default.
• W2462168748 hasRelatedWork W2502524943 @default.
• W2462168748 hasRelatedWork W2523669856 @default.
• W2462168748 hasRelatedWork W2524130482 @default.
• W2462168748 hasRelatedWork W2548157737 @default.
• W2462168748 hasRelatedWork W2561647909 @default.
• W2462168748 hasRelatedWork W2586435830 @default.
• W2462168748 hasRelatedWork W2590111115 @default.
• W2462168748 hasRelatedWork W2598051070 @default.
• W2462168748 hasRelatedWork W2980906462 @default.
• W2462168748 isParatext "false" @default.
• W2462168748 isRetracted "false" @default.
• W2462168748 magId "2462168748" @default.
• W2462168748 workType "article" @default.